ENTA - Enanta Pharmaceuticals Inc. (ENTA) Q1 2024 Earnings Call Transcript
2024-02-07 22:04:03 ET
Enanta Pharmaceuticals, Inc. (ENTA)
Q1 2024 Earnings Conference Call
February 07, 2024, 04:30 PM ET
Company Participants
Jennifer Viera - IR
Jay Luly - President and CEO
Paul Mellett - CFO
Scott Rottinghaus - Chief Medical Officer
Tara Kieffer - Chief Product Strategy Officer
Conference Call Participants
Roy Buchanan - JMP
Roanna Ruiz - Leerink
Amy Li - Jefferies
Eric Joseph - JPMorgan
Presentation
Operator
Good afternoon and welcome to Enanta Pharmaceuticals' Fiscal First Quarter Financial Results Conference Call. At this time, all participants are on a listen-only mode. There will be a question-and-answer session at the end of the prepared remarks. Please be advised that this call is being recorded.
I would now like to turn the call over to Jennifer Viera, Investor Relations. Please go ahead.
Jennifer Viera
Thank you, operator, and thanks to everyone for joining us this afternoon. The news release with our fiscal first quarter financial results, was issued this afternoon and is available on our website.
Making remarks on today's call are Dr. Jay Luly, President and Chief Executive Officer; and Paul Mellett, our Chief Financial Officer. Dr. Scott Rottinghaus, our Chief Medical Officer; and Dr. Tara Kieffer, our Chief Product Strategy Officer, will be available during the Q&A portion of this call.
Before we begin with our formal remarks, we want to remind you that we will be making forward-looking statements, which may include our plans and expectations with respect to our research and development pipeline and financial projections, all of which involve certain assumptions and risks beyond our control that, could cause our actual developments and results to differ materially from those statements....
Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript